Pipeline Update: Status of Clinical Development for Multiple Sclerosis
July 20th 2021The development of agents for MS to address the treatment needs of patients with progressive and relapsing disease has been an ongoing effort that has brought forth a few new potential disease-modifying therapies.
Identifying Atypical Forms, Presentations of Demyelinating Disease: Oliver Tobin, MBBCh, BAO, PhD
July 20th 2021The associate professor of neurology at Mayo Clinic Rochester discusses the importance of alternative diagnoses and rarer presentations of MS, in order to avoid misdiagnoses and inappropriate treatment for patients.
Implementing and Maintaining Telehealth for Alzheimer Disease: Jessica Zwerling, MD, MS
July 19th 2021Challenges surrounding the use of telehealth for patients with Alzheimer disease are affected by technological barriers, according to the associate director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease
Telehealth for Patients with Alzheimer Disease: Jessica Zwerling, MD, MS
July 19th 2021The director of the Montefiore Hudson Valley Center of Excellence for Alzheimer’s Disease discusses the use of telehealth for patients with Alzheimer disease during the COVID-19 pandemic, as well as her thoughts on why it is here to stay.
Biogen and InnoCare Reach Collaboration Agreement for BTK Inhibitor Orelabrutinib
July 18th 2021Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.
Mayo Clinic: Institutional Perspectives in Neurology, Chaired by Brian G. Weinshenker, MD
July 16th 2021Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]
Adopting Consensus Guidelines for MRI in MS: Scott D. Newsome, DO; David Li, MD, FRCPC
July 15th 2021Implementing new recommendations for the use of MRI in patients with MS will be a challenge in terms of education and adherence; Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the next steps to increase awareness for both patients and providers.